For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Alliance A021806

Trial Overview

Official Title

Testing The Use Of The Usual Chemotherapy Before And After Surgery For Removable Pancreatic Cancer

Study Purpose

To determine if receiving chemotherapy before and after surgery will increase the chance of pancreatic cancer staying away.

Diagnosis

Patients have removable pancreatic cancer.

Eligibility

Patient must be candidate for curative intent pancreatectomy to be confirmed by central radiologic review

No prior treatment

Measurable disease

Adeno or adenosquamous cell type

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

This study has a screening step to determine if the cancer is removable by surgery. If removable, patients will continue with the study.

  • Group 1: Patients will receive FOLFIRINOX, the usual four-drug regiment used to treat this type of cancer, for 8 cycles, then have surgery to remove the pancreatic cancer,  then the patient will get FOLFIRINOX for 4 more cycles.
  • Group 2: Patients will receive FOLFIRINOX, the usual four-drug regiment used to treat this type of cancer. Patients will have surgery to remove the pancreatic cancer, and then will get FOLFIRINOX for 12 cycles.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Phase
Phase III
Methodist Health System Trial Code
A021806
Related Specialties